key: cord-0749223-87n3ofpu
authors: Checkmahomed, Liva; Pont, Venice Du; Riola, Nicholas C.; Perry, Jason K.; Li, Jiani; Porter, Danielle P.; Boivin, Guy
title: In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance
date: 2022-02-11
journal: bioRxiv
DOI: 10.1101/2022.02.07.479493
sha: fe4d90d12365a132da9aa97e0302784bdd9cffb9
doc_id: 749223
cord_uid: 87n3ofpu

In vitro selection of remdesivir-resistant SARS-CoV-2 revealed the emergence of a V166L substitution, located outside of the polymerase active site of the nsp12 protein, after 9 passages. V166L remained the only nsp12 substitution after 17 passages at a final concentration of 10 µM RDV, conferring a 2.3-fold increase in EC50. When V166L was introduced into a recombinant SARS-CoV-2 virus, a 1.5-fold increase in EC50 was observed, indicating a high in vitro barrier to RDV resistance.

Remdesivir (RDV; VEKLURY ® ), a nucleotide prodrug inhibitor of the SARS-CoV-2 37 RNA-dependent RNA polymerase (nsp12) is one of the few approved antiviral drugs for 38 the treatment of 2) . Characterization of clinical resistance development to 39 this compound is currently in progress. So far, in vitro resistance to this antiviral has been 40 rarely reported in SARS-CoV-2 and other viruses (3, 4) . 41 In this study, we sought to select an RDV-resistant virus by serial passaging of a wild- (EC 50 ) values were determined by a plaque reduction assay (5) and the nsp12 genotype 51 was determined by PCR amplification followed by Sanger sequencing.

Each non-silent nsp12 substitution was introduced into a recombinant SARS-CoV-2-53 Nano luciferase (Nluc) reporter virus. The reverse genetics system and the procedures 54 required to assemble and produce SARS-CoV-2 infectious strains have been previously 55 described in detail by Xie et al. (6) . Antiviral activity (EC 50 value) of RDV against 56 SARS-CoV-2-Nluc was evaluated with a luciferase assay as reported (7) with some 57 modifications.

Briefly, A549-hACE2 cells were seeded at 12,000 cells per well in medium containing triphosphate (RDV-TP) was generated from the cryo-EM structure 6XEZ (8) as described 72 elsewhere (9). V166 was substituted to an L, and all residues within 5 Å of this residue 73 were conformationally sampled and minimized for both WT and V166L (10).

January 12, 2022. The tabulated amino acid substitutions from Wuhan-Hu-1 reference 76 sequence (NC_045512) for each SARS-CoV-2 sequence (variant surveillance package) 77 were downloaded through GISAID web portal (https://www.gisaid.org/) to assess the 78 prevalence of the mutation.

The V166L substitution located in the nsp12 protein was detected after 9 passages 81 reaching 6 µM of RDV (Table 1) 

Remdesivir for the Treatment of 139 Covid-19 -Final Report

Report of the 146 National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by 151 the Viral Polymerase and the Proofreading Exoribonuclease

In vitro selection of 155 Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by 159 Dalcetrapib

An Infectious cDNA Clone of SARS-CoV-2

A 165 nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-166 infective drugs for COVID-19

Structural Basis for

Coupling in the SARS-CoV-2 Replication-Transcription Complex

Efficient incorporation and template-dependent polymerase inhibition are major 173 determinants for the broad-spectrum antiviral activity of remdesivir

Schrödinger Software Release 2021-3. 2021. Schrödinger, LLC

Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent

GS-5734 and its parent nucleoside analog inhibit Filo

SARS-CoV-2 evolution during 190 treatment of chronic infection

RDV-TP) with a V166L 203 substitution (magenta) in SARS-CoV-2 nsp12 (green). V166L is outside of the active site 204 but contacts Motif A (cyan) and Motif D (pink) residues. Nsp7 and nsp8 are visible in 205 white and yellow, respectively. The nascent RNA